As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of NeuroPace Inc. The largest reported stake is Mathew P. Arens', at 12.25%. 8 filings are on record since August 5, 2025 (Schedule 13G/A, September 4, 2026).
Sell to companies like NeuroPace Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: First Light Asset Management, LLC · Sole voting: 0 · Shared voting: 4,043,931 · Sole dispositive: 0 · Shared dispositive: 4,043,931 · SCHEDULE 13G/A, 2026-09-04
- · Reporting person: OrbiMed Advisors LLC · Sole voting: 0 · Shared voting: 1,505,125 · Sole dispositive: 0 · Shared dispositive: 1,505,125 · SCHEDULE 13G/A, 2026-08-14
- · Holder: OrbiMed Advisors LLC · Percent: 6.2% · SCHEDULE 13G/A
- · Holder: Mathew P. Arens · Percent: 8.67% · SCHEDULE 13G
- · Holder: Soleus Capital Management, L.P. · Percent: 8.9% · SCHEDULE 13G/A
NeuroPace Inc has 8 Schedule 13D or 13G filings on record since 2025-08-05. 3 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 12.25% | 4,203,931 | SCHEDULE 13G/A, 2026-09-04 | 2026-08-31 | |
| Soleus Capital Management, L.P. | 8.9% | 2,948,828 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 |
| Soleus Capital Management, L.P. | 7% | 2,303,828 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 |
| OrbiMed Advisors LLC | 4.4% | 1,505,125 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Kck Ltd. | 0% | 0 | SCHEDULE 13G/A, 2025-09-03 | 2025-02-20 |
Holding shares or following this stake? See who's behind NeuroPace Inc and the warning signs.
Free to see. No signup.
Keep reading
More on NeuroPace Inc and the records around it.
NeuroPace Inc elsewhere on the record
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Soleus Private Equity Fund I, L.P. also filed stake reports on 23 other companies: Evolus, Inc. (Aug 2026), Processa Pharmaceuticals, Inc. (Aug 2026), CERUS CORP (Aug 2026)
- OrbiMed Advisors LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch NeuroPace Inc
Get an email when NeuroPace Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NeuroPace Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NeuroPace Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NeuroPace Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 0 | 4,043,931 | 0 | 4,043,931 | SCHEDULE 13G/A, 2026-09-04 |
| Mathew P. Arens | 130,000 | 4,073,931 | 130,000 | 4,073,931 | SCHEDULE 13G/A, 2026-09-04 |
| OrbiMed Advisors LLC | 0 | 1,505,125 | 0 | 1,505,125 | SCHEDULE 13G/A, 2026-08-14 |
| OrbiMed Capital GP VI LLC | 0 | 1,505,125 | 0 | 1,505,125 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies NeuroPace Inc by CUSIP 641288105 and gives its principal executive office as 455 N. Bernardo Avenue, Mountain View, CA 94043 (SCHEDULE 13G/A, 2026-09-04).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Soleus Capital Management, L.P. | 7% | SCHEDULE 13G/A |
| 2025-08-14 | OrbiMed Advisors LLC | 8% | SCHEDULE 13G/A |
| 2025-09-03 | Kck Ltd. | 0% | SCHEDULE 13G/A |
| 2025-11-07 | Soleus Capital Management, L.P. | 8.9% | SCHEDULE 13G/A |
| 2026-05-15 | OrbiMed Advisors LLC | 6.2% | SCHEDULE 13G/A |
| 2026-05-15 | Mathew P. Arens | 8.67% | SCHEDULE 13G |
| 2026-08-14 | OrbiMed Advisors LLC | 4.4% | SCHEDULE 13G/A |
| 2026-09-04 | Mathew P. Arens | 12.25% | SCHEDULE 13G/A |
Questions about who owns NeuroPace Inc
Who owns NeuroPace Inc?
On this page, 3 holders' latest ownership filings report 5% or more of NeuroPace Inc: Mathew P. Arens (12.25%, Schedule 13G/A, filed 2026-09-04), Soleus Capital Management, L.P. (8.9%, Schedule 13G/A, filed 2025-11-07) and Soleus Capital Management, L.P. (7%, Schedule 13G/A, filed 2025-08-05).
Who are the largest shareholders of NeuroPace Inc?
By the share each holder's latest filing reports, the largest holders of NeuroPace Inc on this page are Mathew P. Arens (12.25%), Soleus Capital Management, L.P. (8.9%) and Soleus Capital Management, L.P. (7%).
When did Mathew P. Arens buy into NeuroPace Inc?
The filings give report dates, not purchase dates. The earliest filing from Mathew P. Arens on this page is the Schedule 13G, filed 2026-05-15, reporting 8.67%; its latest, Schedule 13G/A filed 2026-09-04, reports 12.25%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for NeuroPace Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.